查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018058

肺動脈高壓市場：按藥物類別、給藥途徑、分銷和最終用戶分類－2026-2032年全球市場預測

Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺動脈高壓市場價值將達到 97.7 億美元，到 2026 年將成長至 104.6 億美元，到 2032 年將達到 164.5 億美元，複合年成長率為 7.73%。

主要市場統計數據
基準年 2025 97.7億美元
預計年份：2026年 104.6億美元
預測年份 2032 164.5億美元
複合年成長率 (%) 7.73%

簡要概述肺動脈高壓的臨床複雜性、不斷發展的治療方案以及影響醫療保健服務和投資的策略重點。

肺動脈高壓是一種複雜的進行性性血管疾病，及時診斷、不斷發展的治療方法和協調的護理路徑共同決定著患者的預後。過去幾年，該領域的治療選擇已從有限的幾種轉向多種治療策略，這些策略結合了血流動力學管理、症狀控制和減少長期併發症。臨床醫生現在除了不斷擴充的藥物治療手段外，還將復健和基於風險的追蹤等支持性療法納入治療方案，以提高患者的功能能力和存活率。

臨床創新、不斷發展的交付平台以及支付方和醫療保健提供者的優先事項如何共同重塑肺動脈高壓的治療策略和商業性方法。

肺動脈高壓領域正經歷一場變革，主要得益於科學進步、給藥模式創新以及支付方期望的轉變。近期臨床進展已將治療選擇從傳統的血管擴張劑擴展到聯合治療、難治性疾病治療策略以及以便利性和依從性為優先的新型給藥系統。因此，治療路徑正變得更加個人化，並基於血流動力學特徵、合併症管理以及患者意願進行調整。

2025 年美國關稅措施對肺動脈高壓供應鏈、採購趨勢和取得策略的累積營運和商業影響。

美國2025年實施的新關稅措施對肺動脈高壓的供應鏈和商業規劃產生了多方面的影響。最直接的影響集中在成品和活性成分進口成本的增加上，這些產品和活性成分均來自海外供應商，迫使製造商調整籌資策略和庫存政策。為此，一些相關人員加快了近岸外包的步伐，並實現了供應商多元化，以降低關稅變化帶來的風險，同時確保關鍵治療方法的持續供應。

透過對治療領域、給藥途徑、分銷管道和最終用戶類型進行策略性細分分析，最佳化肺動脈高壓的臨床引入和商業性定位。

清晰了解市場細分動態對於建立差異化的臨床和商業性策略至關重要。我們的藥物類別分析著重考察了內皮素受體拮抗劑、5型磷酸二酯酶抑制劑和類前列腺素藥物，並認知到每類藥物都有其獨特的療效特徵、監測要求和耐受性權衡，這些因素都會影響處方模式和治療路徑。例如，類前列腺素通常需要特殊的給藥和監測，而口服製劑通常降低了門診治療的門檻，從而影響其被納入藥物推廣清單和用藥依從性計劃。

美洲、歐洲、中東和非洲以及亞太地區在臨床路徑、監管預期和准入基礎設施方面的區域差異，正在推動差異化策略的發展。

區域趨勢對臨床實務模式、法規環境和醫療服務取得策略有顯著影響。在美洲，領先的醫療中心和專科轉診網路在早期診斷和複雜治療的實施中發揮核心作用。同時，支付方的多樣性導致了各種不同的保險政策，需要製定個人化的報銷策略。因此，該地區的相關人員通常專注於展示實際療效和成本效益，以確保相關處方集並促進更廣泛的應用。

老牌製造商、創新新參與企業和策略聯盟如何塑造肺動脈高壓領域的競爭動態、證據生成方法和商業化進程？

肺動脈高壓領域的競爭格局呈現出兩極化的特點：既有擁有深厚臨床合作關係的老牌企業，也有提供差異化製劑和給藥技術的新興參與企業。老牌企業繼續專注於產品生命週期管理、循證醫學證據的積累，並致力於加強與轉診醫療機構和專科藥房的合作關係。同時，新參與企業則利用其獨特的市場定位，例如新型給藥系統、標靶聯合治療或以患者為中心的支持項目，在特定的醫療機構和患者群體中站穩腳跟。

領導者面臨的可操作的策略挑戰是：協調臨床證據、供應彈性、支付方參與和病患支持，以加快招募速度並維持醫療服務可及性。

產業領導者應推動一系列切實可行的舉措，以增強臨床療效和商業性韌性。首先，應重點關注相關人員的關鍵結果，例如功能恢復能力、避免住院和治療耐受性，並將真實世界數據 (REW) 的創建與符合支付方和醫療服務提供者決策標準的臨床開發計劃相結合。其次，應制定產品生命週期策略，評估替代製劑和給藥系統，以提高用藥依從性並擴大門診管理能力。

為了支持結論和建議，我們將對臨床醫生進行訪談，對指南和監管進行分析，對供應鏈進行評估，並對相關人員進行核實，從而進行強力的檢驗。

本分析的調查方法結合了多種途徑，整合了臨床、商業和政策的見解。主要調查包括對臨床醫生、專科藥劑師和醫療系統採購經理進行結構化訪談，以了解實際的診療路徑、管理挑戰和合約優先事項。次要調查系統地回顧了同行評審的臨床文獻、監管核准文件和指南更新，以確保臨床聲明反映了當前的醫療標準。

整合治療創新、營運要求和區域/細分市場優先事項，以確定肺動脈高壓的進入和啟動路徑。

總之，肺動脈高壓正處於一個十字路口，治療創新、實際應用挑戰以及不斷變化的支付方期望交織在一起。治療選擇的逐步擴展，加上給藥方式和數位監測的進步，為改善患者預後創造了真正的機會。然而，要實現這一潛力，需要在供應鏈韌性、與支付方的合作以及為臨床醫生和患者提供的支持體系方面做出共同努力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺動脈高壓市場：依藥物類別分類

  • 內皮素受體拮抗劑
  • 磷酸二酯酶-5抑制劑
  • 類前列腺素

第9章 肺動脈高壓市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：按通路分類的肺動脈高壓市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 肺動脈高壓市場：依最終用戶分類

  • 學術和研究機構
  • 診所
  • 醫院

第12章 肺動脈高壓市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺動脈高壓市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺動脈高壓市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肺動脈高壓市場

第16章：中國肺動脈高壓市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation
Product Code: MRR-030D347B0AD6

The Pulmonary Arterial Hypertension Market was valued at USD 9.77 billion in 2025 and is projected to grow to USD 10.46 billion in 2026, with a CAGR of 7.73%, reaching USD 16.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.77 billion
Estimated Year [2026] USD 10.46 billion
Forecast Year [2032] USD 16.45 billion
CAGR (%) 7.73%

Concise contextual overview of pulmonary arterial hypertension clinical complexity, evolving therapeutic options, and strategic priorities shaping care delivery and investment

Pulmonary arterial hypertension represents a complex, progressive vascular disease where timely diagnosis, evolving therapeutics, and coordinated care pathways converge to determine patient outcomes. Over the past several years, the field has transitioned from a narrow set of treatment options toward diversified therapeutic strategies that combine hemodynamic management with symptom control and long-term morbidity reduction. Clinicians now integrate an expanding pharmacologic toolkit alongside supportive measures such as rehabilitation and risk-based follow-up to improve functional capacity and survival.

In addition, clinical practice increasingly emphasizes earlier identification through systematic screening in high-risk populations, combined with multidisciplinary care teams that include cardiologists, pulmonologists, and specialized nursing staff. Simultaneously, regulatory bodies have refined approval pathways for novel agents and formulations, accelerating the availability of new options while heightening the importance of real-world evidence to demonstrate comparative effectiveness. As a result, institutions and industry stakeholders must recalibrate clinical, operational, and commercial strategies to align with contemporary care standards and payer expectations.

This introduction outlines the interplay between therapeutic innovation, clinical practice evolution, and stakeholder priorities, setting the stage for a detailed examination of market dynamics, segmentation patterns, regional nuances, and actionable recommendations presented in subsequent sections.

How clinical innovation, delivery platform evolution, and payer and provider priorities are jointly reshaping therapeutic strategies and commercial approaches in pulmonary arterial hypertension

The pulmonary arterial hypertension landscape is undergoing transformative shifts driven by scientific progress, delivery model innovations, and shifting payer expectations. Recent clinical advances have expanded the therapeutic armamentarium beyond traditional vasodilators to include combination regimens, refractory disease strategies, and novel delivery systems that prioritize convenience and adherence. Consequently, treatment pathways are becoming more individualized, informed by hemodynamic profiling, comorbidity management, and patient preferences.

Beyond pharmacology, digital health tools and remote monitoring are emerging as critical enablers of proactive disease management, facilitating earlier detection of deterioration and improving medication adherence. At the same time, manufacturers are exploring differentiated formulations-ranging from oral agents to parenteral prostanoids-that balance efficacy with tolerability and patient lifestyle considerations. Supply chain resilience and pricing transparency have ascended on the stakeholder agenda, prompting manufacturers and providers to optimize procurement strategies and contract terms.

Taken together, these shifts demand agile commercial planning, closer alignment between clinical development and real-world evidence generation, and greater collaboration across providers, payers, and advocacy groups to translate therapeutic advances into measurable improvements in patient outcomes.

The cumulative operational and commercial consequences of 2025 United States tariff measures on pulmonary arterial hypertension supply chains, procurement dynamics, and access strategies

The introduction of new tariff measures in the United States during 2025 created a multi-dimensional impact on the pulmonary arterial hypertension supply chain and commercial planning. Immediate effects centered on increased import costs for finished products and active pharmaceutical ingredients sourced from international suppliers, which in turn prompted manufacturers to reassess sourcing strategies and inventory policies. In response, several stakeholders accelerated nearshoring initiatives or diversified supplier portfolios to mitigate exposure to tariff volatility while preserving continuity of critical therapies.

Moreover, tariffs affected contract negotiation dynamics between manufacturers, distributors, and health systems. Procurement teams sought clearer pass-through provisions and risk-sharing mechanisms to stabilize unit costs for hospitals and specialty pharmacies. Simultaneously, payers and hospital pharmacy committees demanded greater transparency on cost drivers, creating pressure for manufacturers to justify pricing differentials and to explore patient assistance or rebate programs to minimize therapy disruption for vulnerable patients.

In aggregate, the tariff environment heightened the importance of supply chain visibility and strategic procurement. Going forward, organizations that invest in supplier diversification, incremental manufacturing capacity in tariff-exempt jurisdictions, and robust scenario planning will be better positioned to sustain access and manage commercial relationships amid ongoing global trade policy uncertainty.

Strategic segmentation analysis linking therapeutic classes, administration routes, distribution channels, and end-user types to optimize clinical adoption and commercial positioning in pulmonary arterial hypertension

A clear understanding of segmentation dynamics is essential to craft differentiated clinical and commercial approaches. Analysis by drug class explicitly considers Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Prostanoids, recognizing that each class carries distinct efficacy profiles, monitoring requirements, and tolerability trade-offs that influence prescribing patterns and care pathways. For instance, prostanoids often require specialized administration and monitoring, while oral agents typically lower barriers to outpatient management, which affects formulary placement and adherence programs.

When evaluated by route of administration, distinctions among Intravenous, Oral, and Subcutaneous therapies create divergent logistical and patient-experience implications. Intravenous treatments necessitate infusion infrastructure and skilled nursing support, whereas subcutaneous options can blend outpatient administration with home-based care models. Oral agents, meanwhile, expand opportunities for primary-care involvement and broaden access but raise adherence and drug-drug interaction considerations that clinicians must manage.

Distribution channels, including Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, exhibit unique operational and regulatory constraints that shape channel strategy. Hospital pharmacies manage acute and parenteral therapy delivery and often drive formulary decisions, whereas online and retail pharmacies expand convenience for chronic outpatient regimens and require tailored patient support services. Finally, end-user segmentation across Academic & Research Institutions, Clinics, and Hospitals identifies where clinical expertise, trial activity, and volume-based purchasing intersect, guiding where to focus education, clinical trial enrollment efforts, and contracting strategies.

Regional nuances in clinical pathways, regulatory expectations, and access infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated strategies

Regional dynamics materially influence clinical practice patterns, regulatory environments, and access strategies. In the Americas, centers of excellence and specialized referral networks play a central role in early diagnosis and complex therapy administration, while payer heterogeneity drives varied coverage policies that require tailored reimbursement strategies. As a result, stakeholder engagement in this region often emphasizes demonstrating real-world outcomes and cost-effectiveness to secure favorable formulary positions and facilitate broader adoption.

Across Europe, the Middle East & Africa, healthcare systems range from centralized national procurement models to more fragmented, private-sector-driven channels. These differences shape pricing negotiations, access timelines, and market entry sequencing. Stakeholders must therefore align clinical evidence packages with region-specific health technology assessment expectations and deployment infrastructures, paying special attention to capacity for parenteral therapy delivery and specialist training where prostanoids or infusion therapies are indicated.

In the Asia-Pacific region, rapid adoption of oral and simplified administration regimens is frequently driven by efforts to expand access within constrained specialty care networks. At the same time, expanding diagnostic programs and growing investments in cardiovascular specialty centers create opportunities for targeted launches and partnership models that accelerate clinician education and patient identification. Collectively, these regional nuances necessitate differentiated launch and access strategies that respect local clinical practice, regulatory pathways, and distribution capabilities.

How incumbent manufacturers, innovative entrants, and strategic partnerships are shaping competitive dynamics, evidence generation approaches, and commercialization in pulmonary arterial hypertension

The competitive landscape in pulmonary arterial hypertension is defined by a mix of established players with deep clinical partnerships and emerging entrants that offer differentiated formulations or delivery technologies. Established manufacturers continue to focus on lifecycle management, evidence generation, and strengthening relationships with referral centers and specialty pharmacies. At the same time, newer entrants leverage niche positioning-such as novel delivery systems, targeted combination therapies, or patient-centric support programs-to secure footholds in specific care settings and patient cohorts.

Strategic collaborations between pharmaceutical developers, academic centers, and device manufacturers are increasingly common, reflecting a shift toward integrated therapeutic solutions that combine pharmacology with administration or monitoring innovations. Licensing agreements and co-development partnerships help accelerate access to complementary technologies while distributing development risk. Meanwhile, contract manufacturing and supply partnerships are central to ensuring continuity for parenteral products that require sterile fill-finish capabilities and specialized cold chain logistics.

Overall, companies that align clinical development with pragmatic implementation plans-investing in provider education, reimbursement support, and robust post-launch evidence generation-are best positioned to convert clinical promise into sustainable clinical adoption and durable institutional relationships.

Actionable strategic imperatives for leaders to align clinical evidence, supply resilience, payer engagement, and patient support to accelerate adoption and sustain access

Industry leaders should pursue a set of pragmatic, actionable initiatives to strengthen clinical impact and commercial resilience. First, align clinical development plans with real-world evidence generation that addresses payer and provider decision criteria, focusing on outcomes that matter to stakeholders such as functional capacity, hospitalization avoidance, and treatment tolerability. Second, design product lifecycle strategies that evaluate alternative formulations and delivery systems to enhance adherence and broaden outpatient management capabilities.

Third, reinforce supply chain resilience by diversifying suppliers, validating secondary manufacturing sites for critical parenteral therapies, and establishing contractual mechanisms that mitigate trade policy volatility. Fourth, invest in tailored payer engagement, developing dossiers that reflect regional health technology assessment requirements and supporting integrated reimbursement pathways through pilot performance-based arrangements where feasible. Fifth, prioritize clinician and patient education programs that simplify initiation and titration protocols, particularly for therapies that require specialized monitoring or infusion support.

Finally, cultivate partnerships across distributors, specialty pharmacies, and digital health providers to extend patient support services, optimize adherence, and capture real-world outcomes. These combined actions will help organizations convert scientific advances into meaningful patient benefit while maintaining commercial viability amid evolving policy and care delivery environments.

Robust triangulation of clinician interviews, guideline and regulatory analysis, supply chain evaluation, and stakeholder validation to underpin conclusions and recommendations

The research methodology for this analysis combines a triangulated approach to synthesize clinical, commercial, and policy intelligence. Primary research included structured interviews with treating clinicians, specialty pharmacists, and health-system procurement leaders to capture real-world care pathways, administration challenges, and contracting priorities. Secondary research entailed systematic review of peer-reviewed clinical literature, regulatory approval documentation, and guideline updates to ensure clinical assertions reflect current standards of care.

Analysts also evaluated supply chain configurations and trade policy developments through supplier interviews and publicly available regulatory filings to assess operational implications. Evidence synthesis balanced clinical efficacy data with implementation feasibility, paying particular attention to differences in administration requirements and distribution channels. Wherever possible, findings were corroborated across multiple sources to strengthen validity and to minimize single-source bias.

Finally, stakeholder feedback sessions with clinicians and payer advisors were used to validate conclusions and refine recommendations, ensuring that the final analysis aligns with frontline experiences and decision-making criteria across diverse healthcare settings.

Integrated synthesis of therapeutic innovation, operational imperatives, and regional and segmental priorities that determines access and adoption trajectories in pulmonary arterial hypertension

In conclusion, pulmonary arterial hypertension is at an inflection point where therapeutic innovation intersects with practical delivery challenges and evolving payer expectations. The incremental expansion of treatment options, coupled with advances in delivery modalities and digital monitoring, creates real opportunities to improve patient outcomes. However, realizing that potential requires coordinated attention to supply chain resilience, payer engagement, and clinician and patient support systems.

Strategic segmentation-considering drug class, route of administration, distribution channels, and end-user contexts-enables more precise targeting of education, access, and contracting initiatives. Regional nuances further demand tailored approaches that align evidence packages with local regulatory and procurement structures. Importantly, recent policy shifts and tariff dynamics underscore the need for scenario planning and diversified sourcing to preserve access to critical therapies.

Collectively, stakeholders that integrate rigorous evidence generation with pragmatic implementation plans and robust operational safeguards will be best positioned to translate clinical advances into sustained improvements in patient care and institutional value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Arterial Hypertension Market, by Drug Class

  • 8.1. Endothelin Receptor Antagonists
  • 8.2. Phosphodiesterase-5 Inhibitors
  • 8.3. Prostanoids

9. Pulmonary Arterial Hypertension Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Pulmonary Arterial Hypertension Market, by Distribution

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Pulmonary Arterial Hypertension Market, by End User

  • 11.1. Academic & Research Institutions
  • 11.2. Clinics
  • 11.3. Hospitals

12. Pulmonary Arterial Hypertension Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pulmonary Arterial Hypertension Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pulmonary Arterial Hypertension Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pulmonary Arterial Hypertension Market

16. China Pulmonary Arterial Hypertension Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alembic Pharmaceuticals Limited
  • 17.6. AstraZeneca PLC
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Bayer AG
  • 17.9. Boehringer Ingelheim GmbH
  • 17.10. Cipla Limited
  • 17.11. CMP Pharma, Inc.
  • 17.12. Dr. Reddy's Laboratories Limited
  • 17.13. Eli Lilly and Company
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Gossamer Bio, Inc.
  • 17.17. Gyre Therapeutics, Inc.
  • 17.18. Hikma Pharmaceuticals PLC
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lupin Limited
  • 17.21. Merck KGaA
  • 17.22. Novartis AG
  • 17.23. Pfizer, Inc.
  • 17.24. Sun Pharmaceutical Industries Limited
  • 17.25. Teva Pharmaceutical Industries Ltd.
  • 17.26. Torrent Pharmaceuticals Limited
  • 17.27. United Therapeutics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)